ArticleScience (New York, N.Y.)2015
HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.
Abstract read
In one paragraph
Article in Science (New York, N.Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
155citing papers in PubMed, 1 pooled it
14.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
155 citing papers in PubMed, 1 synthesis or guideline pooled it, 202 citations in OpenAlex.
- Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens.EBioMedicine · 2022Pooled it
- Effects of sex but not race and geographic origin on vaccine-induced HIV-specific antibody responses.Frontiers in immunology · 2025Trial
- Fecal microbiota transplantation in HIV: A pilot placebo-controlled study.Nature communications · 2021Trial
- Effect of a Nutritional Intervention on the Intestinal Microbiota of Vertically HIV-Infected Children: The Pediabiota Study.Nutrients · 2020Trial
- Natural Immunity to HIV is associated with Low BLyS/BAFF levels and low frequencies of innate marginal zone like CD1c+ B-cells in the genital tract.PLoS pathogens · 2019Trial
- Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination.PloS one · 2019Trial
- HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.Proceedings of the National Academy of Sciences of the United States of America · 2018Trial
- Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.The Journal of infectious diseases · 2018Trial
- Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.PLoS pathogens · 2017Trial
- Trial
- Trial
- Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.Cancer cell · 2026Article
- Article
- A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adults.medRxiv : the preprint server for health sciences · 2026Article
- Cell-free RNA reveals host and microbial correlates of broadly neutralizing antibody development against HIV.PLoS pathogens · 2026Article
- Article
- Gut microbiota as a regulator of vaccine efficacy: implications for personalized vaccination.Gut microbes · 2025Review
- Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand.Open forum infectious diseases · 2025Article
- Modulation of oral vaccine efficacy by the gut microbiota.NPJ vaccines · 2025Review
- Antibiotic-induced gut microbiome perturbation alters the immune responses to the rabies vaccine.Cell host & microbe · 2025Article
95 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors at 9 institutions in 2 countries.
Wilton B WilliamsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA. barton.haynes@duke.edu wilton.williams@duke.edu.
Hua-Xin LiaoDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
M Anthony MoodyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Thomas B KeplerDepartment of Microbiology, Boston University School of Medicine, Boston, MA, USA.
S Munir AlamDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Feng GaoDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Kevin WieheDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Ashley M TramaDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Kathryn JonesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Ruijun ZhangDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Hongshuo SongDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Dawn J MarshallDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
John F WhitesidesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Kaitlin SawatzkiDepartment of Microbiology, Boston University School of Medicine, Boston, MA, USA.
Axin HuaDepartment of Microbiology, Boston University School of Medicine, Boston, MA, USA.
Pinghuang LiuDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Matthew Z TayDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Kelly E SeatonDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Xiaoying ShenDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Andrew FoulgerDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Krissey E LloydDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Robert ParksDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Justin PollaraDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Guido FerrariDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Jae-Sung YuDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Nathan VandergriftDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
David C MontefioriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Magdalena E SobieszczykDepartment of Medicine, Columbia University Medical Center, New York, NY, USA.
Scott HammerDepartment of Medicine, Columbia University Medical Center, New York, NY, USA.
Shelly KarunaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Peter GilbertThe Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Doug GroveThe Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Nicole GrunenbergVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
M Juliana McElrathVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Richard A KoupVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Lawrence CoreyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Gary J NabelVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Cecilia MorganThe Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Gavin ChurchyardThe Aurum Institute, Johannesburg, South Africa.
Janine MaenzaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Michael KeeferUniversity of Rochester School of Medicine, Rochester, NY, USA.
Barney S GrahamVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Lindsey R BadenBrigham and Women's Hospital, Boston, MA, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA. barton.haynes@duke.edu wilton.williams@duke.edu.
Duke University · USFred Hutch Cancer Center · USBoston University · USColumbia University Irving Medical Center · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USAurum Institute · ZABrigham and Women's Hospital · USUniversity of Rochester · US
Funding
LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6MLC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6MSDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9MVirus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7MHarvard Medical School Vaccine Clinical Trials UnitUM1AI069412 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Lindsey Robert Baden, Daniel R. Kuritzkes · 2012 to 2026
$57.2MSocial and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5MColumbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8MUniversity of Rochester HIV/AIDS Clinical Trials Unit Administrative SupplementUM1AI069511 · NIAID · UNIVERSITY OF ROCHESTER · PI Paul R Bohjanen, MICHAEL C KEEFER · 2012 to 2026
$25.7MSeattle Vaccine Trials UnitUM1AI069481 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Rachel Ann Bender Ignacio, Margaret Juliana McElrath · 2012 to 2026
$24.4MTesting of Blood Samples for Immune Response and Vaccine ResearchZIAAI005073 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KOUP, RICHARD A · 2009 to 2025
$23.4MHarvard Medical School Vaccine Clinical Trials UnitU01AI069412 · NIAID · HARVARD MEDICAL SCHOOL · PI DOLIN, RAPHAEL · 2007 to 2011
$5.4MIntramural NIH HHSNIAID NIH HHS P30 AI064518NIAID NIH HHS P30-AI-64518NIAID NIH HHS U01 AI069412NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1AI068618NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI069412NIAID NIH HHS UM1 AI069470NIAID NIH HHS UM1 AI069481NIAID NIH HHS UM1 AI069511NIAID NIH HHS UM1 AI100645
Abstract
An HIV-1 DNA prime vaccine, with a recombinant adenovirus type 5 (rAd5) boost, failed to protect from HIV-1 acquisition. We studied the nature of the vaccine-induced antibody (Ab) response to HIV-1 envelope (Env). HIV-1-reactive plasma Ab titers were higher to Env gp41 than to gp120, and repertoire analysis demonstrated that 93% of HIV-1-reactive Abs from memory B cells responded to Env gp41. Vaccine-induced gp41-reactive monoclonal antibodies were non-neutralizing and frequently polyreactive with host and environmental antigens, including intestinal microbiota (IM). Next-generation sequencing of an immunoglobulin heavy chain variable region repertoire before vaccination revealed an Env-IM cross-reactive Ab that was clonally related to a subsequent vaccine-induced gp41-reactive Ab. Thus, HIV-1 Env DNA-rAd5 vaccine induced a dominant IM-polyreactive, non-neutralizing gp41-reactive Ab repertoire response that was associated with no vaccine efficacy.
Indexed as
AdenoviridaeAIDS VaccinesAntibodies, MonoclonalAntibody FormationCross ReactionsHIV-1HIV AntibodiesHIV Envelope Protein gp120HIV Envelope Protein gp41HumansImmunityImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionImmunologic MemoryIntestinesMicrobiotaAIDS VaccinesAntibodies, MonoclonalHIV AntibodiesHIV Envelope Protein gp120HIV Envelope Protein gp41Immunoglobulin Heavy ChainsImmunoglobulin Variable RegionVaccines, DNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.